Table 1.
Compd | R2 | R3 | R4 | R5 | R6 | IC50(µM)a |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MCF-7 | 2774 | SKOV-3 | HL-60 | Hep 3B | H460 | COLO 205 | A498 | Detroit 551 | |||||||
Un-substituted | |||||||||||||||
12a | H | H | H | H | H | 18.5 | >30 | >30 | >50 | >50 | >50 | >50 | 42.7 | >50 | |
Mono-substituted | |||||||||||||||
12b | OCH3 | H | H | H | H | 27.1 | 18.8 | 26.6 | 10 | 23.3 | >25 | 18.1 | 9.8 | >25 | |
12c | H | OCH3 | H | H | H | 14.9 | 15.6 | 24.6 | >10 | >10 | >10 | 39.6 | >50 | >10 | |
12d | H | H | OCH3 | H | H | >30 | >30 | 26.8 | >20 | >20 | >20 | >50 | >25 | >20 | |
Di-substituted | |||||||||||||||
12e | OCH3 | H | OCH3 | H | H | 6.0 | 0.4 | 0.4 | 0.4 | 1.0 | 0.9 | 7.4 | 48 | >25 | |
12f | OCH3 | H | H | OCH3 | H | 3.7 | 6.5 | 20 | 3.5 | 10 | 10 | 6.1 | 28.9 | >100 | |
12g | OCH3 | H | H | H | OCH3 | 29.8 | >30 | >30 | >100 | >100 | >100 | >50 | >50 | >100 | |
12h | H | OCH3 | OCH3 | H | H | 14.3 | 6.6 | 6.4 | 4.1 | 14.6 | 14.4 | 16.8 | 25.6 | 23.6 | |
12i | H | OCH3 | H | OCH3 | >30 | 8.3 | >30 | 2.9 | >10 | >10 | >50 | 11.7 | >10 | ||
Tri-substituted | |||||||||||||||
12j | OCH3 | H | OCH3 | H | OCH3 | 21 | >30 | >30 | 75 | >100 | 67.6 | 37.4 | >50 | >100 | |
12k | H | OCH3 | OCH3 | OCH3 | H | 4.5 | 2.1 | 0.93 | 2.3 | 5.0 | 7.6 | >50 | >50 | >25 | |
Fluoro-substituted | |||||||||||||||
121 | F | H | H | H | H | >30 | 26.4 | >30 | >100 | >100 | >100 | >50 | >50 | >100 | |
12m | H | H | H | H | >30 | 24.5 | >30 | >20 | >20 | >20 | >50 | >50 | >20 | ||
12n | H | H | F | H | H | >30 | 17.6 | >30 | >60 | >20 | >20 | >50 | >50 | >20 | |
Etoposide | 5.48 | 1.0 | |||||||||||||
5-FU | 22.3 | 26.7 |
Human tumor cells were treated with different concentrations of samples for 48 h (n = 3 independent experiments).
Data are presented as IC50 (µM, the concentration of 50% proliferation-inhibitory effect).